NET PROFIT (x1000 EUR)
NeoProteomics AB
Closing information (x1000 EUR)
| Closing information | 2022/12 | 2021/12 | 2020/12 |
| Turnover |
0
|
0
|
0 |
| Financial expenses |
4
|
5
|
5 |
| Earnings before taxes |
-10
|
-6
|
-26 |
| EBITDA |
-6
|
-2
|
-21 |
| Total assets |
519
|
556
|
568 |
| Current assets |
10
|
2
|
4 |
| Current liabilities |
400
|
422
|
425 |
| Equity capital |
120
|
134
|
143 |
| - share capital |
10
|
11
|
11 |
| Employees (average) |
0
|
0
|
0 |
Financial ratios
| Fiscal year | 2022/12 | 2021/12 | 2020/12 |
| Solvency |
23.1%
|
24.1%
|
25.2% |
| Turnover per employee | |||
| Profit as a percentage of turnover | |||
| Return on assets (ROA) |
-1.2%
|
-0.2%
|
-3.7% |
| Current ratio |
2.5%
|
0.5%
|
0.9% |
| Return on equity (ROE) |
-8.3%
|
-4.5%
|
-18.2% |
| Change turnover |
0
|
0
|
0 |
| Change turnover % | |||
| Chg. No. of employees |
0
|
0
|
-2 |
| Chg. No. of employees % | -100% |
Total value of public sale
| Fiscal year | 2022/12 | 2021/12 | 2020/12 |
| Total value of public sale |
0
|
0
|
0 |
Closing figures are converted to the currency above at the exchange rate of the closing date. Source for the exchange rates: Sveriges Riksbank
The closing information is gathered directly from the companies or from Creditsafe.